Fulcrum Therapeutics Presents Updated Data on Sickle Cell Disease Program at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition
CAMBRIDGE, Mass., Dec. 05, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the...